Kingsview Wealth Management’s XORTX Therapeutics XRTX Stock Holding History

Kingsview Wealth Management’s Portfolio XRTX Stock Details XRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,000	Closed	-$6.13K	–	1531
2026 Q1	$6.13K	Buy	+3,000	New	+$7K	﹤0.01%	1331

Other funds holding XRTX

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Kingsview Wealth Management's XRTX Position: Q2 2026 in Review

Kingsview Wealth Management sold out of XORTX Therapeutics (XRTX) in Q2 2026, closing a stake of 3,000 shares — an estimated $6.13K sold.

Kingsview Wealth Management first reported a position in XRTX in Q1 2026 and held it in 1 quarter. The position peaked at $6.13K in Q1 2026. 6 funds tracked by Wall St. Rank hold XRTX as of Q2 2026.

Kingsview Wealth Management reported no remaining XORTX Therapeutics position as of Q2 2026 after selling out during the quarter.
Kingsview Wealth Management sold 3,000 XORTX Therapeutics shares in Q2 2026, an estimated $6.13K.
Kingsview Wealth Management first reported a position in XORTX Therapeutics in Q1 2026 and held it in 1 quarter.
Kingsview Wealth Management's XORTX Therapeutics position peaked at $6.13K in Q1 2026.
6 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.